Literature DB >> 14656875

Natural history of GATA1 mutations in Down syndrome.

Momin Ahmed1, Alexander Sternberg, Georgina Hall, Angela Thomas, Owen Smith, Aengus O'Marcaigh, Robert Wynn, Richard Stevens, Michael Addison, Derek King, Barbara Stewart, Brenda Gibson, Irene Roberts, Paresh Vyas.   

Abstract

Acquired mutations in megakaryocyte transcription factor GATA1 have recently been reported in Down syndrome (DS), transient myeloproliferative disorder (TMD), and acute megakaryoblastic leukemia (AMKL). To provide novel insight into GATA1 mutations in DS, genomic DNA was assayed from 12 AMKL and 4 TMD cases (including neonatal, prediagnosis samples in 4 of 16), neonatal blood spots from 21 DS children without clinically evident TMD or AMKL, and 62 non-DS cord blood samples, using techniques not previously employed with such samples. GATA1 mutations were present in all TMD and AMKL cases and at birth in 3 of 4 children without known clinical TMD, who later developed AMKL. They were present at birth in 2 of 21 DS neonates, who have not yet, but could still, develop AMKL (now 26 and 31 months). GATA1 mutations were not detected in 62 non-DS cord blood samples. In 4 AMKL patients multiple independent GATA1 mutations were observed. These data show GATA1 mutations occur in utero in most DS TMD and AMKL, that they may occur without clinical signs of disease, and that multiple separate GATA1 mutant clones can occur in an individual. The findings have implications for pathogenesis of DS TMD and AMKL and highlight parallels between DS AMKL and other childhood leukemias.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656875     DOI: 10.1182/blood-2003-10-3383

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Life-threatening complications of transient abnormal myelopoiesis in neonates with Down syndrome.

Authors:  Sabine Dormann; Marcus Krüger; Roland Hentschel; Regina Rasenack; Brigitte Strahm; Udo Kontny; Charlotte Niemeyer
Journal:  Eur J Pediatr       Date:  2004-04-28       Impact factor: 3.183

Review 2.  Topics in pediatric leukemia--myelodysplastic and myeloproliferative disorders of childhood.

Authors:  Joseph Lasky; Kathleen M Sakamoto
Journal:  MedGenMed       Date:  2005-03-14

3.  The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor.

Authors:  Barbara Ghinassi; Massimo Sanchez; Fabrizio Martelli; Giovanni Amabile; Alessandro Maria Vannucchi; Giovanni Migliaccio; Stuart H Orkin; Anna Rita Migliaccio
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

4.  Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome.

Authors:  Ming-Horng Tsai; Jia-Woei Hou; Chao-Ping Yang; Pong-Hong Yang; Shih-Ming Chu; Jen-Fu Hsu; Ming-Chou Chiang; Hsuan-Rong Huang
Journal:  Indian J Pediatr       Date:  2011-02-02       Impact factor: 1.967

5.  GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.

Authors:  Su Han Lum; Soo Sin Choong; Shekhar Krishnan; Zulqarnain Mohamed; Hany Ariffin
Journal:  Singapore Med J       Date:  2016-06       Impact factor: 1.858

Review 6.  Evolution of myeloid leukemia in children with Down syndrome.

Authors:  Satoshi Saida
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

Review 7.  Combinations of chromosome transfer and genome editing for the development of cell/animal models of human disease and humanized animal models.

Authors:  Narumi Uno; Satoshi Abe; Mitsuo Oshimura; Yasuhiro Kazuki
Journal:  J Hum Genet       Date:  2017-11-27       Impact factor: 3.172

8.  Single-nucleotide polymorphisms in CD8A and their associations with T lymphocyte subpopulations in pig.

Authors:  Wenwen Wang; Yang Liu; Weixuan Fu; Jingen Xu; Jianfeng Liu; Xiangdong Ding; Qin Zhang
Journal:  Mol Genet Genomics       Date:  2015-02-19       Impact factor: 3.291

Review 9.  Malignancy in children with trisomy 21.

Authors:  Karen R Rabin; James A Whitlock
Journal:  Oncologist       Date:  2009-01-28

10.  Trisomy 21 enhances human fetal erythro-megakaryocytic development.

Authors:  Stella T Chou; Joanna B Opalinska; Yu Yao; Myriam A Fernandes; Anna Kalota; John S J Brooks; John K Choi; Alan M Gewirtz; Gwenn-ael Danet-Desnoyers; Richard L Nemiroff; Mitchell J Weiss
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.